di-DTPA-LTL 

di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with ¹¹¹In (indium) and ¹³¹I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled ¹¹¹In) into the patients^[1][2][3].

1243.27

C₅₂H₈₂N₁₂O₂₃

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gruaz-Guyon A, et al. Recent advances in pretargeted radioimmunotherapy. Curr Med Chem. 2005;12(3):319-38.  [Content Brief]

  [2]. Gautherot E, et al. Therapy for colon carcinoma xenografts with bispecific antibody‐targeted, iodine‐131‐labeled bivalent hapten[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 1997, 80(S12): 2618-2623.  [Content Brief]

  [3]. Aarts F, et al. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F (ab′) 2 antibody[J]. Cancer, 2010, 116(S4): 1111-1117.  [Content Brief]